$121.19
N/A
마지막 업데이트: Oct 13, 4:02 AM
Benzinga
Benzinga
Benzinga
화요일, 10월 13
Benzinga
© 2026 Benzinga | All Rights Reserved
Corcept Therapeutics (CORT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Corcept Therapeutics (CORT)는 7월 29, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $1.1B - $1.2B 범위로 예상했습니다.
이전 가이던스와 비교하여 Corcept Therapeutics는 매출 전망치를 이전 범위인 상향 조정됨에서 $950M - $1.05B로 상향 조정했습니다.
Corcept Therapeutics은 19과 11월 3, 2022 사이에 7월 29, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 13 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.02 | $-0.17 | $0.31 | $0.15 |
| Actual | $0.36 | $-0.30 | $0.20 | $0.16 |
| Surprise | +1700.0% | -76.5% | -35.5% | +6.67% |
| Revenue | ||||
| Estimate | $219.3M | $183.8M | $254.7M | $218.8M |
| Actual | $256.1M | $164.9M | $202.1M | $207.6M |
| Surprise | +16.8% | -10.3% | -20.6% | -5.10% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.83 | $1.16 | $0.43 | $0.78 |
| Revenue | ||||
| Consensus | $334.9M | $389.9M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $0.36 | $0.02 | 1700.0 % |
| Q1 | Apr 30, 2026 | $-0.30 | $-0.17 | -76.5 % |
| Q4 | Feb 24, 2026 | $0.20 | $0.31 | -35.5 % |
| Q3 | Nov 4, 2025 | $0.16 | $0.15 | 6.67 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $256.15M | $219.32M | 16.8 % |
| Q1 | Apr 30, 2026 | $164.90M | $183.78M | -10.3 % |
| Q4 | Feb 24, 2026 | $202.13M | $254.72M | -20.6 % |
| Q3 | Nov 4, 2025 | $207.64M | $218.79M | -5.10 % |